“Just So Grateful.” Artemis II Crew & Eli Lilly’s New GLP-1 Pill 4/30/26

Summary

---

Squawk Pod: “Just So Grateful.” Artemis II Crew & Eli Lilly’s New GLP-1 Pill

Date: April 30, 2026
Hosts: Joe Kernan, Andrew Ross Sorkin, Cameron Costa (Producer), with guest interviews
Main Themes:

• Eli Lilly’s record-breaking quarter and new GLP-1 pill launch
• Historic Artemis II lunar mission and NASA astronauts’ reflections
• Federal Reserve policy tensions and market impact
• AI company Anthropic’s soaring valuation

---

Episode Overview

This episode of Squawk Pod is rich with big stories about technological and scientific frontiers in health, finance, and space. CNBC anchors and reporters offer context, analysis, and exclusive interviews. The main segments cover Eli Lilly’s blockbuster earnings and the rollout of an oral GLP-1 weight-loss drug, in-depth conversations with the returned Artemis II moon crew, discussions on the drama at the Federal Reserve, and a check-in on Anthropic’s eye-popping AI valuation. The tone is enthusiastic, inquisitive, and at times deeply human.

---

Key Discussion Points & Insights

1. Federal Reserve and Market Dynamics

[03:07]–[09:15]

• Fed Meeting Drama: Drama unfolds with four dissents at the latest meeting—a rarity since 1992 (Steve Liesman). Tension mounts over the direction of rate policy and communications under incoming chair Kevin Warsh.
• Economic Data: Rising inflation and surging oil prices dampen hopes for imminent rate cuts, with market futures pricing in little chance of cuts through December.
• Debate on Guidance: Discussion centers on whether to keep forward guidance, with Warsh’s philosophy that, “inflation is a choice.”
• Quote:
  “It was the first time since 1992 we had four dissents... So absent a sharp decline in unemployment or inflation, it’s going to be tougher [for a rate cut].” – Steve Liesman (05:03)

---

2. AI & Tech Valuations: Anthropic’s Rise

[09:33]–[12:50]

• AI Company Valuations: Anthropic is reportedly raising funding at a $900B valuation, outpacing OpenAI’s last mark. Skepticism emerges as these numbers seem increasingly disconnected from fundamental metrics.
• Government Regulation: The White House is considering ways to rein in AI’s pace, potentially to the advantage or detriment of specific players.
• Quote:
  “Because nobody’s marking this. This is all being marked make-believe.” – Andrew Ross Sorkin (10:42)

---

3. Eli Lilly’s Record Quarter and New GLP-1 Pill

[17:31]–[29:42]

• Blowout Earnings: CEO David Ricks shares that Lilly posted a 56% year-over-year revenue increase, driven by weight loss drugs—especially outside the U.S., where volume surged by 95%.

• Global Expansion: Constrained by supply a year ago, now the GLP-1 franchise is booming in markets like Europe, China, Brazil.

• Foundeo (oral GLP-1 pill): The newly launched oral pill is seeing strong organic demand with 20,000+ patients in the first 20 days; over 80% are new to the drug class.

• Innovation Runway: Newer molecules, including RET and Laurelintide, are in the pipeline, promising even greater efficacy.

• Quotes:
  “It turns out people like to lose weight all around the world.” – David Ricks (20:15)
  “We’re super excited by what we’re seeing... more than 80% of the people who’ve initiated Foundao are new, completely new to this category.” – David Ricks (22:46)

• Health Benefits Beyond Weight Loss:
  “We just read out a study that’s pretty interesting that showed we reduced cardiovascular events by 22% in people with diabetes, but also reduced all-cause death by more than 50%.” – David Ricks (28:38)

---

4. NASA Artemis II Astronauts In Studio: Awe, Adventure, and Reflection

[31:26]–[45:57]

• Crew Reflections on Returning Home:
  The Artemis II crew (Reid Wiseman, Victor Glover, Christina Koch, Jeremy Hansen) share a mix of deep gratitude, awe at the lunar sights, and the emotional impact of seeing Earth from afar.

• Memorable Moments & Emotions:
  “At the end of it, the trust the countries and the world had for us to go do the science, but also the poetry and the gratitude. Just so grateful.” – Artemis II crew (32:28)

  • The “Eclipse of the moon and the sun” brings profound wonder: “There were several moments where the only appropriate response was ‘Oh, my God.’” (33:51)

• Human Side: Family & Support:
  Crew members discuss the indispensable support from families and the unique emotional challenges their loved ones faced.

• Technical Challenges:

  • A dramatic but ultimately false smoke/fire alarm, communication with home, and “constellation urine” (a playful reference to a toilet maintenance issue in space).
  • Lunar Living: After going so close, the reality of establishing a lunar base seems much less abstract:
    “Going that close to the moon and seeing that, hey, there is a place… we could have infrastructure to keep us safe. We’re a lot closer than it seemed before we launched.” (36:21)

• Vision for the Future:
  Artemis II sees itself as an “opener of markets”; pushing from low-Earth orbit to the Moon, Mars, and beyond, paralleling historical leaps in transportation and exploration.

• Quotes & Notable Moments:

  • “I have no fear of failure.” – NASA Astronaut (17:02, 30:57)
  • “Just be curious about the world, about everything in it.” – Christina Koch (30:25, 45:40)
  • On Grit:
    “We didn’t show up with the same stuff... The right stuff can make it seem like there’s this kind of standard path... The characteristics are very different [among us].” – Artemis II crew (45:02)

---

Notable Quotes & Memorable Moments

• On Artemis II’s Emotional Impact:
  “At the end of it... the science, but also the poetry and the gratitude. Just so grateful.” – Artemis II crew (32:28)
• On Pharma’s Demand:
  “It turns out people like to lose weight all around the world.” – David Ricks, Eli Lilly CEO (20:15)
• On AI Valuations:
  “Because nobody’s marking this. This is all being marked make-believe.” – Andrew Ross Sorkin (10:42)
• On Astronaut Family Sacrifice:
  “No one really understands how it was to be a family member and watch the four of us leave the planet...” – Christina Koch (34:19)
• On Handling In-Flight Emergencies:
  “We study for two primary emergencies. That’s smoke, fire, and a rapid cabin depress. And we had both of them on our mission.” – Artemis II crew (38:23)

---

Timestamps for Key Segments

• [03:07] – Federal Reserve: Steve Liesman on FOMC drama & dissents
• [09:33] – Anthropic’s AI valuation & market skepticism
• [17:31] – Eli Lilly earnings and exclusive interview with CEO David Ricks
• [20:15] – International explosion in weight-loss drug demand
• [22:46] – Details and early reception of new GLP-1 pill, Foundeo
• [28:38] – Health impact data: Cardiovascular and all-cause mortality
• [31:26] – Artemis II astronauts in studio: emotions and gratitude
• [33:46] – Moments of awe: viewing the Earth, the moon, and “Oh, my God” moments
• [36:21] – The prospect of lunar habitation becomes tangible
• [38:23] – Handling emergencies: smoke alarms & “constellation urine”
• [40:24] – Re-entry feelings and future of space “mass tourism”
• [45:02] – “The right stuff” and the diversity of astronaut backgrounds

---

Episode Tone & Language

The conversation is driven by genuine curiosity, humor, and awe. CNBC’s trademark blend of sharp market analysis and relatable, sometimes lighthearted banter is evident. The Artemis II astronauts, in particular, bring humility, inspiration, and gratitude, making the technical feel personal and urgent.

---

For the Listener

If you missed the episode, know that it highlights the human drive for discovery and progress: whether building drugs that could reshape public health, pushing the limits of AI, or stepping further into the cosmos. The guests’ reflections, especially the Artemis II crew’s sense of gratitude and responsibility, are as riveting as the finance headlines.

---

End of Summary

Transcript

[Julia Boorstin]

Your data lives everywhere on prem in the cloud, across apps. Bring it all together with Everpure, the platform that acts like a living system, delivering the latest in data performance, security and innovation without ever slowing you down. Sophisticated enough to anticipate your ever changing data needs, yet simple enough to feel like second nature. Tame your data chaos with Everpure and make storage and data management the simplest part of your business. Visit everpeardata.com to learn more.

[AT&T Business Wireless Representative]

Not every sale happens at the register before AT&T business Wireless checking out customers on our mobile POS systems took too long. Basically a staring contest where everyone loses. It's crazy what people will say during an awkward silence. Now transactions are done before the silence takes hold. That means I can focus on the task at hand and make an extra sail or two. Sometimes I do miss the bonding time.

[CNBC Narrator]

Sometimes AT&T business Wireless connecting changes everything.

[Producer/Host (possibly Cameron Costa or a show producer)]

Bring in show music please.

[Cameron Costa]

This is Squawk Pod and I'm CNBC producer Cameron Costa. On today's episode, Eli Lilly blowing past expectations in its latest quarter thanks in part to international growth. Now that Lilly's GLP1s have been available in Europe, China and Brazil for a few quarters. CEO David Ricks in an exclusive newsy interview.

[Producer/Host (possibly Cameron Costa or a show producer)]

I think it's answering a question a lot of investors had which is what's the depth, the breadth of the GLP1 weight loss consumer market around the world and here we see just really strong numbers internationally. It turns out people like to lose weight all around the world.

[Cameron Costa]

Ready? Blast off. Artemis II crew has landed on squawks. Set the groundwork. They're laying in space with pilot Victor Glover.

[CNBC Narrator]

Now going that close to the moon and seeing that hey, there is a place down there that we could have infrastructure to keep us safe. I think you know, Reid has mentioned it, if we had a lunar lander we would go and so we're a lot closer than it seemed before we launched.

[Cameron Costa]

And mission specialist Christina Cook on the

[NASA Representative (possibly Reid Wiseman or Victor Glover)]

new frontiers, NASA's job in a lot of ways to open markets and we're doing that on every frontier that we find. As soon as we opened it in low Earth orbit, we're pushing to the lunar market. Eventually it'll be Mars, but there's nothing theoretically preventing us from doing any of that.

[Cameron Costa]

Plus Anthropic's eye popping valuation and a changing of the guard at the Federal Reserve. Steve Leesman is our eye on the Fed.

[Steve Liesman]

We have to have a discussion long, interesting and probably not trending on the Internet about how the Fed is going to change Communication under Kevin Moore.

[Cameron Costa]

It's Thursday, April 30, 2026 and Squawkpod begins right now.

[Producer/Host (possibly Cameron Costa or a show producer)]

Stand Andrew by in 3, 2, 1.

[Mission Specialist Christina Cook]

Q. Andrew,

[Andrew Ross Sorkin]

good morning. Welcome to Squawk box right here on CNBC. We're live the NASDAQ market site in Times Square. Mandras Sorkin along with Joe Kern and Becky is off today.

[Commercial Announcer]

Anyway, thank you very much everyone. I won't see you next.

[Joe Kernan]

Real drama at the Fed meeting and news conference yesterday that sometimes we say that and it's, I don't know, we're kind of Fed. You know, I don't know if the entire country is always talking about drama at the Fed, but this might have broken through yesterday. Liesman, was it trending anywhere? Not quite trending, but.

[Steve Liesman]

But close as you might imagine. Joe, I don't really follow trending things. It's not really my thing to be trending.

[Joe Kernan]

But you are certainly a nerdy Fed head.

[Steve Liesman]

But yes, that is true for you.

[Joe Kernan]

It didn't get anything get any better than yesterday?

[Steve Liesman]

No, it was a good day but for that purpose. But I think I want to reverse things the way you guys were talking about. You guys put Powell at the lead and I think the more important thing is the four dissents, okay, because there is sign a potential sharp debate to come with the Fed over that drop of rates. That was the drama that this nerd was interested. The upshot may be it's going to be difficult for the new Fed chair to deliver rate cuts any time soon. It was the first time since 92 we had four dissents. Three dissenters, all regional bank presidents. They opposed the subtle easing bias in the statement. And one Governor Stephen Myron, as he has every time since he joined the Fed, dissented in favor this time of a quarter point cut. Fed Chair Powell indicated others could join with the dissenters at the next meeting in support of eliminating the easing bias. So absent a sharp decline in unemployment or inflation, it's going to be tougher. The new Fed chair nominee, Kevin Wash to engineer a June rate cut or beyond that assumes he wants one. Here's what's interesting. The dissenters only advocated moving the Fed to where the market is already after yesterday's strong economic data and another surge in oil prices. Futures for December price just a 10% chance of a rate cut, 86% chance of no change. That's all the way through December and a 6% chance of a hike. So the market is in the middle, which is where the senators want to move the Fed. Meanwhile, on the drama that everybody else is talking about. Treasury Secretary Scott Bessett criticized Powell's decision to stay on the board as a governor, saying it was a violation of all Federal Reserve norms. Powell early in his press conference pretty much accused the administration of violating norms as well, saying these legal actions by the administration are unprecedented in our 113 year history.

[Commercial Announcer]

These legal actions by the administration are unprecedented in our 113 year history. And there are ongoing threats of additional such actions. I worry that these attacks are battering the institution and putting at risk the thing that really matters to the public, which is the ability to conduct monetary policy without taking into consideration political factors.

[Steve Liesman]

So that's where we are. I don't think. I'm trying to figure out what's most important to our viewers, Joe. You know, what's trending on the Internet is not always the case. And I think that the centers and the debate over policy is probably the more important of the two. Look, it's going to be.

[Joe Kernan]

The news keeps coming too. And I made the point that, okay, wow, inflation is bad for rate cuts, obviously. Meanwhile, if, if you do believe that there's risk to the labor market and to growth because of oil prices, that argues for rate cut. But then, so now we got Caterpillar. Did you see this today?

[Steve Liesman]

No, I didn't see.

[Joe Kernan]

Okay, Caterpillar is up I think 40 points to an all time high based on construction. Industrial construction up 38%. I mean, is that, is that where you cut rates? What would it be if.

[Steve Liesman]

It is very hard to round.

[Joe Kernan]

Power center, Steve. So air power centers, a lot of, I mean there are, they're not one offs but there's ways you can explain it and maybe the expensing from the big beautiful.

[Steve Liesman]

Let me, I don't know if I gave you these numbers, Joe, but I ran these numbers yesterday in the national accounts. Information processing equipment, year over year up. You want to take a number? Guess, Take a guess. Year over year, percent change.

[Joe Kernan]

I don't want to take a guess.

[Steve Liesman]

33%.

[Joe Kernan]

This was 38.

[Steve Liesman]

Okay, now take out information processing equipment from equipment spending. What is it? What is the rest of the economy up in terms of that investment?

[Joe Kernan]

So it's all that or it's three.

[Steve Liesman]

Okay, so it's all that. That's all coming through. Look, you know, I'm not sure that Kevin wants a cut here. You know, remember he said, he said inflation is a choice. What choice would he make in this? And he said, by the way, he wants this big debate. Let me make another point. It is pretty. It has happened many, many times before that Fed officials have dissented because of the guidance. And what did Kevin say? Get rid of the guidance. So I'm not sure this debate would even happen under Kevin Warsh. He wants to get that out of there. Why are you guiding when you don't know where things are? Would he even have a dot plot in this. In this context? So we have to have a discussion, long, interesting and probably not trending on the Internet about how the Fed is going to change communication under Kevin Marsh.

[Joe Kernan]

So many things that they know more.

[Andrew Ross Sorkin]

Press conference.

[Steve Liesman]

I think there'll be a press conference. Personally, if you asked me.

[Andrew Ross Sorkin]

Yep.

[Steve Liesman]

I was not in favor of the Fed chair going to the press conference every meeting. He explained yesterday why he did that and I think it makes sense why he did it, which is that all of a sudden we had lost the ability to move at every meeting if we needed to because the market was sort of attuned to. To the idea of only when there was a press conference. But I'm just not sure that that was beneficial to the communications process of the Fed to have that every meeting. But it's fine. And they could. And he could go back. He could roll it back. I think maybe a press conference when you need it.

[Joe Kernan]

Right. I think of days of old, there were times when like the Dow kept going up and then you could. You could tie it to a takeover of an oil company or something and people would say, well, it doesn't really count. But it was happening. It didn't matter what it was. So today it's Caterpillar that has the Dow up the S and P might trade in another. I think one of the things we're trying to understand is $110 oil, the market hitting new highs. When does that. Right. We keep asking the question, when does that become a real problem for equities?

[Producer/Host (possibly Cameron Costa or a show producer)]

Talk.

[Steve Liesman]

Talk to Andrew about how much of the economy is moving on silicone and how much is moving on hydro.

[Joe Kernan]

Wait a minute. Silicon. Unless you're talking about breast implants.

[Steve Liesman]

Yeah, I'm not.

[Joe Kernan]

You mean Joe.

[Steve Liesman]

I'm not doing training. Silicone. Silicon.

[Joe Kernan]

No, silicone is totally different than silicon.

[Steve Liesman]

Okay.

[Joe Kernan]

There. There's the. Yeah, there's Silicon Valley and Silicon Valley, which is Beverly Hills. Thank you. Anthropic potential funding milestone for anthropic. CNBC has learned that the AI company is in talks to raise money at a $900 billion valuation that would put it ahead of OpenAI's valuation of $852 billion last month. The source tells CNBC no term sheet has been signed and talks are ongoing. In February, Anthropic was valued at $380 billion. I mean these are the way they move around these, these numbers. The company declining to comment when contacted by cnbc. Do we think that open air. It's constantly going up, obviously. But given the news from a couple of days ago, did at least the rapid increase slow or did it actually get marked back down a little bit based on users? Based on. You're talking about the valuation of what we just said. We just said OpenAI's valuation was X. Right. I'm sure it was already higher because that was a couple like a while ago.

[Andrew Ross Sorkin]

Because nobody's marking this. This is all being marked make believe.

[Joe Kernan]

It seems like you could make up numbers to. To get to where. I mean they're not valued on normal.

[Andrew Ross Sorkin]

No. Well, I mean we're going to talk about this. I imagine this other anthropic story about this Mythos business.

[Joe Kernan]

I know, it just makes me scared.

[Andrew Ross Sorkin]

And the idea that the White House is now talking about trying to slow them down further just because the technology

[Joe Kernan]

is too powerful or.

[Andrew Ross Sorkin]

Well, the power. Here's the question. On one side the argument is the technology is too powerful and that they don't have enough compute power. The argument they are making is they don't have enough compute power.

[Joe Kernan]

Yeah.

[Andrew Ross Sorkin]

And therefore the government, which would want to use Mythos too, wouldn't have enough compute power to actually use it properly, nor would all the companies. And therefore that actually creates its own danger. That is actually a. If that is true and they are worried about that, that is a real problem and not just a real problem. Also is demonstrative of the question mark about whether you need to build more data centers. Because if you don't have the compute power and then by the way, certain people have compute power, certain people don't, then the whole dynamic becomes very, very problematic. Just to know winners and losers and who can actually break into things. That's a wild scenario. If you are cynical and believe that the White House doesn't like anthropic for political purposes, you would try to slow down anthropic as much as possible in a hundred different ways so that others, Maybe Google, maybe OpenAI could eventually have time to catch up. And there's an argument that that may be going on.

[Joe Kernan]

Right. Well, if there's not enough, you know, computing power, then we're not going to spend as much money if that's going to slow that down. And all these things that we've counted on to justify these valuations. Those will you have to question. Yes, those as well. But we have been all along because the numbers, anybody can say trillion just as easy. It's as easy to say trillion as it is to say billion. But I mean it makes a difference. Well, it's a thousand times as much. You know that I'm not great at

[Andrew Ross Sorkin]

math, but I do know that, you

[Joe Kernan]

know, you know what was good scientific notation because it makes everything very clear.

[Steve Liesman]

Right.

[Joe Kernan]

10 to the 6th, 10 to the 9th.

[Andrew Ross Sorkin]

If you believe that. By the way, you know, we keep talking about the anthropic potential IPO and the open air ipo, then you have to start to mark down and worry about the space X IPO because a portion of that Space X market cap is X. Now people have already marked down some of that because there's real questions about sort of what kind of success they're going to have with that model. Where it is now, by the way, this anthropic story could also the the White House anthropic story could help X again, another company that is trying to catch up to where they are. Are you excited about this next story? Yes. Okay. Saudi Arabia's public investment fund is going to end support for the upstart Live golf league this after this year's season is completed. It's according to sources who spoke with cnbc and they're telling us that a committee of independent directors will evaluate strategic alternatives for the league after Saudi Arabia pulls funding. LIVE is expected to lay out details about its future today, including adding new board members and working to secure new long term financial partners. LIVE declined to comment. Split the world of golf when it founded back in 2021, created a massive more than a soap opera geopolitical one and of course you remember poached some of the top sports players, really upended the PGA in so many ways and a fascinating situation but also a note that that Saudi and others in the Middle east are pulling back from investments. Joe, in the US I don't know if you saw Matt Bellany's latest newsletter. He says that there should be some consideration or thought about what's going on with the Paramount deal with Warner Brothers which might well include some of some money from the Middle east and some money that petro, Petro money if you will.

[Producer/Host (possibly Cameron Costa or a show producer)]

Cheese will be next.

[Cameron Costa]

Coming up on Squawk Pod, a big quarter for Eli Lilly and for weight loss drugs. A new weight loss pill hit the market in April and CEO David Ricks shares the data. So far, it's a conversation you will only hear on CNBC.

[Producer/Host (possibly Cameron Costa or a show producer)]

We've been out in the market about 20 days. We've got over 20,000 patients using our product at this point. I can tell you today it'll be a lot more than a thousand a day going on. The product is growing nicely. But just recall like our ramp is going to be a little different because it's a new brand, a new molecule. Does that change our long term outlook? No.

[Cash App Advertiser]

Is Bitcoin complicated or do people just think it is? For a long time it felt like something only tech experts or hardcore investors really understood. Between all the headlines, new terminology and everything people say about it, it can seem harder than it needs to be. But what if getting started with Bitcoin didn't have to feel overwhelming? If you've been curious about Bitcoin but haven't made the jump yet, Cash App makes it easy. You can set up automatic purchases with zero fees or buy larger amounts also with zero fees. Start small or go bigger. It's designed to be simple. Either way, for a limited time, new customers get $10 added to their balance. Just use code CASH APP10 when you sign up. And don't forget this part. Send at least $5 to a friend in the first two weeks. Terms apply. Cash App is a financial services platform, not a bank. Banking services provided by Cash App's bank partners. Bitcoin services provided by Block Inc. Brand for additional information, see the Bitcoin disclosures at Cash App legalpodcast Before we

[AT&T Business Wireless Customer]

had AT and T Business wireless coverage, our delivery GPS wasn't the most reliable. Once our driver had to do a 14 point turn to get back on route. A 14 point turn. An influencer even live streamed the whole thing. Not good for business. Now with AT&T business Wireless, routes are updating on the fly and deliveries are on time. And the influencer did get us 53 new followers though.

[CNBC Narrator]

AT&T business Wireless connecting changes everything.

[Joe Kernan]

What made you confident that you could do something that hadn't been done before?

[NASA Representative (possibly Reid Wiseman or Victor Glover)]

I have no fear of failure.

[Julia Boorstin]

Trailblazing women Changing the game One of

[AT&T Business Wireless Representative]

my favorite pieces of advice. Think about what your boss's boss needs.

[Cameron Costa]

Leadership can look in many, many different forms. It really does come down to just trusting yourself.

[Julia Boorstin]

Life is short and you just gotta

[Producer/Host (possibly Cameron Costa or a show producer)]

think big to accomplish big things.

[Julia Boorstin]

Julia Boorstin hosts CNBC Changemakers and Power Players. New episodes every Tuesday, wherever you get your podcasts.

[Cameron Costa]

This is Squawk Pod from CNBC Today with Joe Kernan and Andrew Ross Sorkin.

[Producer/Host (possibly Cameron Costa or a show producer)]

Stand by Joe His Mike Q Eli

[Joe Kernan]

Lilly results topping estimates. Revenue is in increase was driven by volume growth but partially offset by lower realized prices for Manjaro in zip bound. And join us now in an exclusive interview. Eli Lilly CEO David Ricks and our own Angelica Peebles is also with us. It's good to see you, David. And you're moving back closer to $1 trillion market cap. These numbers, everything is so far above expectations, obviously. But your stock did hit I think 1100, almost 1150, I think 1133 dollars at one point. So you know, this is all good news. Is it? Is it, would it be expected do you think? Because the weight loss market is so hot, but there are pricing pressures. Anything surprising to you?

[Producer/Host (possibly Cameron Costa or a show producer)]

Well, thanks for having me on. Obviously we had a really strong start to the year, beating expectations. Yes. But you know, I think impressively it's like our fifth or sixth quarter in a row posting really strong top line growth numbers here, 56% revenue growth year over year. That's not usually something pharmaceutical companies of our size do. And I think it's answering a question a lot of investors had which is what's the depth, the breadth of the GLP1 weight loss consumer market around the world. And here we see just really strong numbers internationally across every geography. Strength in the US market across both forms, Zeppbound and Manjaro. And the team's executing really well. We're also excited. We launched our oral pill just a few weeks ago. Off to a strong start there. We're on track with our expectations. And that's the first new brand and new molecule that's launched with obesity in the sort of the modern era. So we're out there building that brand and so far the reception and the buzz is very good. And on top of that, Joe, we're investing a lot in the pipeline, our own organic pipeline, you see the R and D numbers, but also making a few more acquisitions lately to really bolster our long term growth. So companies in a really good place and these are, you know, it's a strong start to the year. We're very confident in a good year ahead.

[Joe Kernan]

You're raising guidance pretty much across the board, but I'm sure that the people that follow your company were already getting a lot more positive on the guidance. Can you just explain for people, how does revenue outside the U.S. increase 81%, I mean, or volume, 95% increase? Are these people just discovering weight loss drugs or something?

[Producer/Host (possibly Cameron Costa or a show producer)]

How does that happen? To be honest, yes. You may recall, I mean it seems like a long time ago Maybe to us, but just in late 24, we had pretty much like global supply constraints on these medications and Lilly and our competitor had sort of slowed down global introductions here. Now we're hitting our third or fourth quarter in the major markets across Europe, China, Brazil, populous countries where a lot of this, this purchasing is consumer. Right. They're paying out of pocket. And I think as those launches have hit stride, you're seeing the breadth and the depth of that consumer market here, which is very strong. It turns out people like to lose weight all around the world and they're getting the health benefits and seeing real results. We know Tirzepatide, Monjaro and Zepbound is the most effective agent you can use. And, and we're seeing great adoption really around the world and continued growth in the U.S. i mean, Zeppelin's growing something like 70% year over year in the quarter. That's incredible to me. And it's a very scaled product. I think Tirzepatite in total now annualizing around $50 billion.

[Angelica Peebles]

Morning, David. Angelica, thanks for joining us. You know, I have to ask about phone day on that launch. I know it's only been a few weeks, but investors are hanging on to really every scrap of data they can get about those prescriptions. So what can you tell us about the scripts that you've seen so far and how you feel like that pill is stacking up against the Wegovy pill?

[Producer/Host (possibly Cameron Costa or a show producer)]

Yeah, I'm happy to answer that. I know people are watching this run. You know, this is one of the most closely watched launches I can remember. But just a couple, like, background things to remember. First of all, it's not analogous to when we launched Zepbound, which was already available in a medicine called Manjaro. It's the same form. It's not analogous to the Novo product either because they use the same brand name. We have to build a brand and establish a new medicine. You know, doctors aren't going to write medicine they've. They've never heard of. Right. So we, we have to go out and educate them. It's going to take some time. Access needs to kick in and of course, we need to build consumer awareness. And we're not yet on TV and advertising our product. So what we're seeing now is basically organic demand, which is pretty strong to us. We've probably in the last, we've been out in the market about 20 days. We've got over 20,000 patients using our product at this point. I can tell you today it'll be a lot more than 1,000 a day going on. The product is growing nicely. But just recall, like our ramp is going to be a little different because it's a new brand, a new molecule. Does that change our long term outlook?

[CNBC Narrator]

No.

[Producer/Host (possibly Cameron Costa or a show producer)]

We're super excited by what we're seeing and maybe similar to the competitor so far, more than 80% of the people who've initiated Foundao are new, completely new to this category of drugs. So it's, it's very expansionary. I think we saw that with a competitor, we're seeing with ours in terms of the class opportunity here. And that's very positive from our perspective. So on track. I'm really pleased with the execution so far. This is going to play out over quarters, not days. Angelica. And just ask people to take a beat and let us execute. I think it's going to be just fine.

[Andrew Ross Sorkin]

Hey, David, you know, given how we've, we've, we've been seeing each other at a couple different places over, over the past couple of months, always getting into a discussion about sort of where this all goes. When you look at a pill like this that's out there now, do you say this has a Runway life, a long term Runway life, or do you think that things actually are moving so quickly in this space that two, three, four years from now you're going to have so many more advanced versions of this that, that the last pillar, for example, or some of the drugs in the past won't be able to be effectively amortized over time in the same way?

[Producer/Host (possibly Cameron Costa or a show producer)]

Well, it's hard to predict, you know, too far into the future. It has been a fast moving category and we think of our role, Andrew, is just to keep innovating. But if you think of Foundao in its role, it's kind of unique because it's, it's very easy to take. It's hard to imagine designing a medicine that would be as easy as just and any time of day, you know, once a day oral pill. We're so used to that routine. With other medications we take over the counter or prescription. And this will really not be a thing for people to worry about as they go through their day. It's really made for the everyday world. It's also super scalable. And to Joe's earlier question, you know, there are a billion people on the planet who could benefit from these medications. Will we ever reach a billion? I don't know. But right now we're reaching about 20 million. So there's a big Runway in front of us. And from a cost and a scalability perspective, using organic chemistry is a lot more efficient than what we have to do creating auto injectors with peptides, et cetera, which just doesn't seem possible.

[Andrew Ross Sorkin]

No, I guess the reason I'm asking the question is people are, you know, people are already excited about ReTA for example, and whether everyone's going to be on Reta and therefore they're not going to be taking this pill. That's, I guess that's where I'm going with just the innovation.

[Producer/Host (possibly Cameron Costa or a show producer)]

Yeah, choice is good and we're going to offer, I mean, RET is our product. Right. And we hope to introduce that next year, by the way, in a few weeks or a month's time, we'll get our first big obesity readout. And the sign so far is this is going to be really maybe as much as 50% better than tirzepatide. That could be incredible. But that's not for everybody, right? Not everyone needs to lose that much weight. Foundeo people on fondao lose about 20 to 30 pounds. And when we survey consumers in the US and European, actually that's a lot of what people want to do is lose a bit of weight. Something like Tirzepatide is closer to 50 pounds. That's Zepbound and Retta, if you think about it could be 70 plus. So depending on your situation, you might choose a different option. We've got other options coming too, by the way. Two others entered the phase three development in the last six months. A Laurelintide, which is an highly selective amylin agonist which promises like GLP1 like efficacy, but really with very different, much more benign side effect profile. That's an interesting product for some. And then also Brinepatide, which is like a son of Tirzepatide. We're studying for many new medical uses like brain health and inflammation. So I think this story will continue to play out with different choices. But it's hard to think of something being occupying that place for the masses, for the everyday routine, something like Fondeo. It really feels like a great fit for that segment.

[Angelica Peebles]

Really quick, I want to talk about M and A because you guys, guys have been on quite a spree this year doing bigger deals and doing more deals than we're used to seeing from you. So what else should we expect to see this year and where do you feel like you still have holes that you need to fill?

[Producer/Host (possibly Cameron Costa or a show producer)]

Well, we said as we were exiting last year, given the outlook for the company, which is getting a lot bigger quickly and producing a lot of cash flow that we really would prefer to invest that cash flow in future growth. There's a limit to how quickly we can pace out our own organic growth. Probably the best dollar invested in health care in the last 10 years has been a dollar we gave to the Lilly research lab scientists. It's been incredible performance, but there's a limit to how many we can bring on board and how quickly we can efficiently scale. So we're going to supplement that with great teams and great assets from outside the company and open the aperture a bit on the kinds of deals we do. You may be surprised to learn in the last couple of years, Lilly has done more business development deals than any company in pharma. But we tend to be very focused on early stage small things because those to us can produce the highest roi. But we're opening up the aperture to include select assets that are in the clinic that can add to our growth story and have teams around them. Maybe a series of assets that can really help us grow in the future, like the Sentessa acquisition which is modulating sleep and awakening cycles. They have multiple assets, a great team there. We think that's a potentially large TAM opportunity and is the kind of thing you should expect Lilly to do more of in the coming years. We did like four deals in a month that was a little unusual for us. So that's just lumpy in terms of how they've come in. But you can expect a continuous cadence of acquisitions like that.

[Joe Kernan]

Been ticking higher as you've been talking, David. Now 914. It's up about I think more than $60 this morning for, for Eli Lilly. We appreciate bringing all that to us. I'm getting testimonials from people that, that, that are saying it not for just weight loss, that their health is like,

[Producer/Host (possibly Cameron Costa or a show producer)]

I mean that's important. Andrew asked about, about the pill and so forth. We just read out a study that's pretty interesting that showed we reduced Cardiovascular events by 22% in people with diabetes, but also reduced all cause death by more than 50%. So I think people are really interested in those health benefits and as well as the weight loss. So yeah, it's an exciting time for chronic disease. We can really make a big difference here.

[Joe Kernan]

It is amazing what, you know, even like sleep apnea. I mean it's bizarre how many things if, if you're overweight. It's like all bad things come from that.

[Producer/Host (possibly Cameron Costa or a show producer)]

It seems like an all zepbound is indicated for sleep apnea. It's the only new medicine for that

[Joe Kernan]

and you wouldn't think of that.

[Producer/Host (possibly Cameron Costa or a show producer)]

Half the people who take it.

[Joe Kernan]

Yeah.

[Producer/Host (possibly Cameron Costa or a show producer)]

Half the people who take it have no sleep apnea at the end of the study. It's incredible joint pain. We're 150 year old company. I have to mention that we're going to celebrate our birthday next week. And we've never been in a stronger position and in a position to help more people than today.

[Joe Kernan]

Well, we appreciate you coming on Squawkbox on earnings day most of the time, David, thanks.

[Producer/Host (possibly Cameron Costa or a show producer)]

Yeah, absolutely. Great to be with you guys. Take care.

[Cameron Costa]

Next up on Squawk Pod. We're going to space. Well, space explorers are coming to us. The Artemis 2 crew has landed on set and mission specialist Jeremy Hansen gives us some tips for how to feel like an astronaut here on Earth.

[Astronaut Jeremy Hansen]

I've been really intentional with taking my kids on backpacking trips and just getting off the grid and getting out there in nature. I think that is one way that people can experience a small part of what we did. We had some incredible views, but it felt a lot like camping.

[Cameron Costa]

What makes an astronaut extraordinary? Pilot Victor Glover and Commander Reid Wiseman.

[CNBC Narrator]

Asking questions but then listening. That has been a game changer for my trajectory.

[Mission Specialist Christina Cook]

Just be curious about the world, about

[Cameron Costa]

everything in it and who's ready to go back. Mission specialist Christina Cook, the first woman to travel beyond low Earth orbit and the first woman to orbit the moon.

[Joe Kernan]

So which was it? You ready to go to Mars or you can't wait to get back? It's both.

[NASA Representative (possibly Reid Wiseman or Victor Glover)]

Attention is real. It's time to let our friends do that, though. We're ready to cheerlead for Artemis 3 and Artemis IV.

[Cameron Costa]

We are taking off right after this.

[Joe Kernan]

What made you confident that you could do something that hadn't been done before?

[NASA Representative (possibly Reid Wiseman or Victor Glover)]

I have no fear of failure.

[Julia Boorstin]

Trailblazing women, changing the game.

[AT&T Business Wireless Representative]

One of my favorite pieces of advice, think about what your boss's boss needs.

[Cameron Costa]

Leadership can look in many, many different forms. It really does come down to just trusting yourself.

[Julia Boorstin]

Life is short and you just gotta

[Producer/Host (possibly Cameron Costa or a show producer)]

think big to accomplish big things.

[Julia Boorstin]

Julia Boorstin hosts CNBC Changemakers and power players. New episodes every Tuesday. Wherever you get your podcasts,

[Cameron Costa]

Welcome back to Squawk Pod.

[Joe Kernan]

You're watching Squawk Box on cnbc. I'm Joe Kernan along with Andrew Ross Sorkin.

[Andrew Ross Sorkin]

One of the defining stories of the year and one of future generations that may read about it in School is NASA's Artemis 2 mission. The historic flight was a critical step in NASA's plan to return humans to the moon. Joining us right now, fresh off of a stop at the White House and the moon is the Artemis 2 crew. At our table, no less, Joe Kernan. Unbelievable. Reid Wiseman, Victor Glover, Christina Cook and Jeremy Hansen. They're all here. And it is awesome. So it's been a couple of weeks, but how do you feel now? I mean, you're sort of on the tour, but how do you. I mean, did you. Do you go to sleep at night thinking about what it was like being up there at this point still? I do, yes.

[Astronaut Jeremy Hansen]

Oh, absolutely.

[NASA Representative (possibly Reid Wiseman or Victor Glover)]

Yeah. I think we prioritize the last couple of weeks, being back, being with family, for sure. Enjoying Earth and just processing and internalizing what just happened.

[Andrew Ross Sorkin]

What's the biggest. What's the biggest internalizing, processing part for you?

[CNBC Narrator]

I'd say gratitude. All of the thoughts, the views, the camaraderie at the end of it that the trust the countries and the world had for us to go do. The science, but also the poetry and the gratitude. Just so grateful.

[Joe Kernan]

Love that. I've seen two takes, and I don't know which of you said it. One was that if we were headed for Mars, you guys were ready to go. Even though it could be. It could be six months, it signed me up. I saw someone else, said that they couldn't help but think. And this makes me emotional, but looking down at the Earth about their family and how much they. How distant their family was from them. And that feeling which I get when I fly over to Europe, I think I look down at the ground and think, they're so far away. And I feel the loss. And so which was it? You ready to go to Mars or you can't wait to get back? It's both.

[NASA Representative (possibly Reid Wiseman or Victor Glover)]

That tension is real.

[Mission Specialist Christina Cook]

It is real.

[CNBC Narrator]

Yes.

[Andrew Ross Sorkin]

It's real.

[Joe Kernan]

Because you might be different. You do it. Maybe. I'm not sure at this point.

[Andrew Ross Sorkin]

I want to go. Just out of curiosity.

[NASA Representative (possibly Reid Wiseman or Victor Glover)]

Yeah.

[Joe Kernan]

I think seeing what you describe as the eclipse of the moon and the sun is. No human ever even contemplated seeing that in person. And do you feel close to God when that.

[CNBC Narrator]

I think, you know, I will tell you.

[Joe Kernan]

I mean, everybody's different. I understand, but you must.

[CNBC Narrator]

There were several moments where the only appropriate response was, oh, my God. And I. It just was in the DNA. That was the only appropriate response for some of the things that we saw. And that was definitely one of those moments.

[Andrew Ross Sorkin]

What did your families think while you were up there before? What were the conversations like the night before? That's what I want.

[Mission Specialist Christina Cook]

The night before launch.

[Andrew Ross Sorkin]

The night before launch. The night before Launch and, or even maybe months before when you had to say, this is actually happening. We're doing this.

[Mission Specialist Christina Cook]

One of the most amazing parts of this is the support that we have from our families. And I will tell you, I think the thing that they all took away was no one understands except for them. No one really understands. And the four of us, we also don't understand how it was to be a family member and watch the four of us leave the planet, watch us go around the moon. We did have email, and we got two chances to talk to our families while we were up there. It was very special for us. One morning, I woke up about four days into the mission, and my daughter had commented on watching the moon rise the night before from college. And she thought, my dad and his friends are out there, there. And I think that really hit her. But we don't even know what they experienced. But what we do know is the way they supported, the way they showed up for us, and we tried to

[Andrew Ross Sorkin]

show up for them and each other, and each other.

[Joe Kernan]

And if you, if you had a LEM and I don't know if everyone remembers a limb, but if you had a lemon attached, who would have gone? You would have gotten in?

[Andrew Ross Sorkin]

All of us.

[Astronaut Jeremy Hansen]

We all would have gone. Absolutely. The moon was calling you. We're that close. You're looking down at it and you're just like all those rock walls.

[Joe Kernan]

And did you see some potential landing sites?

[Astronaut Jeremy Hansen]

Yeah, all of it.

[Steve Liesman]

You could pretty much.

[Astronaut Jeremy Hansen]

I wanted to go all over the place. I was like, I'd like to go check that out. And I would like to go check that out.

[Joe Kernan]

But there are. There was some work to look and actually scout some places, weren't there?

[Astronaut Jeremy Hansen]

Well, the goal, I mean, there's some really ambitious plans right now for the future Artemis Program to get to the south pole of the moon. We didn't have the best viewing site of the south pole, that that's where we're going to go next. But in the future, we were scouting out areas that eventually will probably have identified some things that probably will go be explored because of what we saw.

[Andrew Ross Sorkin]

Okay, so can you see people really living on the Moon for some period? Like, meaning now that you're. Now that you've done this and seen this, are you like, okay, I get it. It's totally doable. We can have like a whole operation rolling up there. We're going to be using it to take, to put other spaceships from, you know, as a sort of a. Like the jfk. It's going to Be a place people will land and then keep going. We're going to have data centers up there. We're going to. Does that all speak to you? Now?

[CNBC Narrator]

One of the reasons that it is easier to see it was an idea that is now more tangible is because we did that with low Earth orbit. We live in low Earth orbit. We live on the International Space Station. And so now going that close to the moon and seeing that, hey, there is a place down there that we could have infrastructure to keep us safe. I think, you know, Reid has mentioned it. If we had a lunar lander, we would go. And so we're a lot closer than it seemed before we launched.

[NASA Representative (possibly Reid Wiseman or Victor Glover)]

Yeah, the time is right.

[Andrew Ross Sorkin]

What about being just up there for. For long periods of time? When people talk about getting to Mars, for example, do you say to yourself, that's. That feels insane, or do you think, oh, that seems totally reasonable? And. But not just for people going, I'm talking about this en masse. Right? Because the conversations we're having at this table among some of the companies like Space X and others, this is. This is about, you know, potentially thousands, tens of thousands of people doing this.

[NASA Representative (possibly Reid Wiseman or Victor Glover)]

Eventually, you know, NASA's job in a lot of way is to open markets, and we're doing that on every frontier that we find. As soon as we opened it in low Earth orbit, we're pushing to the lunar market. Eventually it'll be Mars. But there's nothing theoretically preventing us from doing any of that, and the time is right.

[Mission Specialist Christina Cook]

Let's also think 100 years ago, if you wanted to go from London to Washington D.C. or New York, think about what that. I mean, you were risking your life to do that. You were probably taking your entire life savings inventing a craft and doing it. And now we hop on an airplane and we, like, we just need to expand, we need to go farther, we need to go past the moon, we need to get to Mars, we need to go beyond Mars. And then you start to pull everything along with you.

[Joe Kernan]

You slept at different times or slept at different times. Anyone sleep at all, or.

[Steve Liesman]

We slept.

[Andrew Ross Sorkin]

We were on one shift.

[NASA Representative (possibly Reid Wiseman or Victor Glover)]

We all slept.

[Andrew Ross Sorkin]

Worked.

[Joe Kernan]

What I'm getting, when the smoke alarm went off, we were awake.

[NASA Representative (possibly Reid Wiseman or Victor Glover)]

During that, we had.

[Joe Kernan]

Who was awake? When the smoke. Everybody was awake.

[Andrew Ross Sorkin]

We were all awake.

[Mission Specialist Christina Cook]

We were still.

[Joe Kernan]

Okay, so you're sitting there, look. Wow, it's nice out there. A smoke alarm goes off and what is the.

[Andrew Ross Sorkin]

What are you thinking?

[NASA Representative (possibly Reid Wiseman or Victor Glover)]

Initial thought, straight to our training.

[Steve Liesman]

Bingo.

[NASA Representative (possibly Reid Wiseman or Victor Glover)]

100%.

[Joe Kernan]

You know, I'd have to go straight to the laboratory?

[Angelica Peebles]

Yeah.

[NASA Representative (possibly Reid Wiseman or Victor Glover)]

We study for two primary emergencies. That's smoke, fire, and a rapid cabin depress. And we had both of them on our mission.

[Joe Kernan]

A rapid.

[NASA Representative (possibly Reid Wiseman or Victor Glover)]

Well, we had enunciations of them, which turned out to not be the case.

[Joe Kernan]

But you thought it was possible for a second.

[Mission Specialist Christina Cook]

Yes, absolutely.

[NASA Representative (possibly Reid Wiseman or Victor Glover)]

When that alarm goes off, Vigilance.

[Andrew Ross Sorkin]

Okay. Has the food gotten any better?

[Joe Kernan]

We didn't find out what was the smoke that wasn't really there. Okay. Both false.

[Mission Specialist Christina Cook]

That was a real fire alarm. It was the emergency sound. It was the only time in the whole mission we had the full emergency sound.

[Joe Kernan]

And when I'd be done, I'm done.

[NASA Representative (possibly Reid Wiseman or Victor Glover)]

No one really, we don't know takes

[Mission Specialist Christina Cook]

automated response, so it shuts down all the power inside and the ventilation down. And now I know what it feels like to be a baked potato inside of an oven.

[Commercial Announcer]

It was.

[Mission Specialist Christina Cook]

It was pretty interesting.

[Andrew Ross Sorkin]

Here's the thing. I think you guys undergo extraordinary amount of training to do this in advance. What would it take for this to work sort of en masse in the future? They're going to have to be people who do basically no training. Right. Because some people are going to be going on vacation to the moon maybe. I don't know. So how would that work, do you think?

[NASA Representative (possibly Reid Wiseman or Victor Glover)]

Honestly, most of our training is for those rare cases of unknown problems happening. So you get a couple of well trained people. And other than that, it's fairly comfortable.

[Andrew Ross Sorkin]

Okay, back to the food. Because everybody always wants to know about the food. My daughter knew that you guys were coming up. What, tell me, is the food gotten any better?

[CNBC Narrator]

Fantastic.

[Mission Specialist Christina Cook]

Food's great.

[CNBC Narrator]

Fantastic.

[Andrew Ross Sorkin]

Highly salted, right? You need a lot of salt up there, apparently to help with the taste.

[CNBC Narrator]

It's challenging because salt would float around the cabin. So we have actually like salt water that we can use to season the food. We have garlic paste. This space station has given us a chance to really flush out our food system. And so we took modifications of the food that we have on the space station. And then you get to pick out a few things. And as long as the packaging is safe for space, we can take things that are just. Just at our local grocery store.

[Andrew Ross Sorkin]

Okay, and what does re entry feel like when you feel. I mean, when we're watching the speed of it, I'm thinking to myself, look, what does that feel like inside that capsule?

[Mission Specialist Christina Cook]

First I want to set it up for you. We were watching the altitude click down six miles a second, about 39 times the speed of sound.

[Andrew Ross Sorkin]

Is that the scariest part of this whole situation is There a moment. How do you rank the different levels?

[CNBC Narrator]

I wouldn't say scary, but it definitely had my attention. For three years. For three years it was that 13 minutes and 36 seconds was, was. Was quite a big focus for me for the whole time.

[Joe Kernan]

You want some? Some. I mean we all remembered the scary things about re entry with tiles and how hot it gets. I guess you're watching for everything at that point.

[CNBC Narrator]

Listening feelings.

[Joe Kernan]

You feel confident though because we've worked so hard on making sure that it can withstand that heat, I guess. Coming.

[Andrew Ross Sorkin]

Does it feel warmer? Like you're very cognizant of that. What's that feel like?

[NASA Representative (possibly Reid Wiseman or Victor Glover)]

Yeah, not right away, but you are looking at a flame right outside the window. That in some cases was so bright it was like looking at an arc welder. I mean it was white hot.

[Andrew Ross Sorkin]

And then when the parachute hit. And you felt that, right?

[Astronaut Jeremy Hansen]

Oh yeah.

[CNBC Narrator]

Glorious, glorious, glorious.

[Astronaut Jeremy Hansen]

It's a very violent feeling and you love it. You're so, so happy for that violent feeling.

[Joe Kernan]

People need to know about it. Need to warn them about it. You said they need future people need to know. You're going to feel like you're falling off a skyscraper backwards.

[Producer/Host (possibly Cameron Costa or a show producer)]

For how long?

[Joe Kernan]

For 30 seconds.

[Astronaut Jeremy Hansen]

Yeah. You have these two stages of parachutes. These drogues come out and there's two of them for a bit, but then they release. And between their release and the main, those big red orange parachutes coming out, you do fall again.

[Joe Kernan]

Okay, you remember what I said? Bill Paxton, he's great. He's gone now. But the consolation urine, right, Orion, what happened with the toilet and what did that. Was it. How long was it out?

[Astronaut Jeremy Hansen]

Did you think I broke?

[Joe Kernan]

People break toilets all the time. I've been accused of that before. But it was only for number one, right? That was the only.

[CNBC Narrator]

So the toilet was fine, but the line we used to empty the liquid part of the toilet out was clogging up. And so what would that mean?

[NASA Representative (possibly Reid Wiseman or Victor Glover)]

Create the constellation.

[Joe Kernan]

Which would create the constellation urine. But then you fix that too though.

[CNBC Narrator]

Well, we adapted now.

[Joe Kernan]

Okay, Secondary.

[Mission Specialist Christina Cook]

There's a primary vent line and that was clogged so we couldn't use the urine part of our official toilet. But we have a secondary vent line and that never clogged up. So we could use a backup system which definitely was not as convenient, but it was workable for the length of maintenance mission we had.

[Andrew Ross Sorkin]

Okay, so who wants to go back? Oh yeah, everybody signed up.

[NASA Representative (possibly Reid Wiseman or Victor Glover)]

It's time to let our friends do that though. We're ready to cheerlead for Artemis 3 and Artemis 4 and see people go back up, do some docking, test out those landers, and eventually.

[CNBC Narrator]

Okay.

[Andrew Ross Sorkin]

Would you want to go the next time with your families? How do you think everyone would do? Everybody all together? No, I was thinking about this because you guys all talk about your families, and I think, oh, maybe everyone should go together. But then I've been in a car ride with all five of us, and sometimes it's complicated. I love it, personally. Anyway, I love to play I Spy

[Steve Liesman]

with my little eyes. We're heading out to the moon with Mike.

[Andrew Ross Sorkin]

Right, Exactly.

[NASA Representative (possibly Reid Wiseman or Victor Glover)]

The Alphabet game.

[Andrew Ross Sorkin]

You wouldn't get really boring.

[Astronaut Jeremy Hansen]

I think you might be surprised because, you know, the way you show up for one another when you're 250,000 miles from Earth, people just stand, too. And a lot of grace. You might be surprised by your family.

[Mission Specialist Christina Cook]

It is.

[Joe Kernan]

I won't go there.

[Andrew Ross Sorkin]

Where are you going to go? We got a whole crowd.

[Joe Kernan]

I was just going to say I'm not going to ask you about Iran or anything. I know you got to ask no questions. We don't need to talk about that. But all we wanted to talk about was your heroism and bravery and everything else, and patriotism. And we thank you for that. I always ask, where do we find people like this? Because don't look here.

[Andrew Ross Sorkin]

Can I go back to that, though? Because this is one thing I was thinking about with kids, actually, which is you guys clearly are brave, courageous. You have something that I wish I had called the right stuff, and I hope my kids have. And people talk about grit and how do you sort of create that? Do you have a sense of whatever you have, and do you think that you've figured out a way to bottle it up for the rest of us?

[Astronaut Jeremy Hansen]

One thing that, you know, I've been really intentional with taking my kids on backpacking trips and just getting off the grid and getting out there in nature and, you know, not having the creature comforts at home. I just. I think that is one way that people can experience a small part of what we did. We had some incredible views, but it's.

[Andrew Ross Sorkin]

But was there something about your childhood's youth? And look, you know, we joke. We have a hard time, you know, screening a light bulb. No, no. So I want to know, like, what was going on.

[CNBC Narrator]

You know, I like where you're going. And I think what I want to say, and I. I'm speaking to especially the young folks, old folks. This applies to us, too, but to the young folks, we didn't show up with the same stuff. We, you know, that term, the right stuff can make it seem like there's this kind of standard path. It's the paths are very different. The characteristics are very different. And NASA will train you the training to get there, learning to go out and backpack safely. But you can come from a lot of different places, but there is a path. And I will tell you one thing that I can look back in my past is you mentioned your kids listening, asking questions, but then listening. That has been a game changer for my trajectory.

[Mission Specialist Christina Cook]

And be curious. Be curious. I think that's the biggest. You see this curiosity in kids. Just be curious about the world, about everything in it.

[Joe Kernan]

You're always curious.

[Andrew Ross Sorkin]

That part we have in spades at this table. Reid, Victor, Christina and Jeremy, thank you on behalf of the American people, on behalf of humanity. Really, it's something.

[Mission Specialist Christina Cook]

Thank you.

[Producer/Host (possibly Cameron Costa or a show producer)]

Thank you.

[Andrew Ross Sorkin]

Unbelievable.

[Joe Kernan]

Thank you.

[CNBC Narrator]

Thanks for having us.

[Cameron Costa]

That's Squawk Pod for today. Thank you for listening. Squawk Box is hosted by Joe Kernan, Becky Quick and Andrew Ross Sorkin. You can tune in to CNBC every weekday morning at 6am Eastern to catch them live for three hours to get the best bits of that broadcast right into your ears. Follow Squawkpod wherever you get your podcasts. We'll meet you right back here tomorrow. Have a great day.

[Producer/Host (possibly Cameron Costa or a show producer)]

We are clear. Thanks, guys.

[Andrew Ross Sorkin]

This is the Chase Sapphire lounge at Boston Logan.

[Commercial Announcer]

You got clam chowder in New York, dirty martini over 1300 airport lounges and one card that gets you in Chase Sapphire Reserve.

[Andrew Ross Sorkin]

Now even more rewarding. Learn [e-mail] Sapphire Reserve cards issued by

[Producer/Host (possibly Cameron Costa or a show producer)]

JP Morgan Chase bank and a member FDIC subject to credit approval.